Starling Oncology SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 5, 2026, 4:57 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedStarling Oncology Q3 2026 revenue of $169.8 million tops $168.7 million consensus, but GAAP EPS of -$0.13 misses -$0.048 and FY2026 revenue guidance is cut to $650-660 million
8-KSept. 1, 2026, 8:41 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KAug. 21, 2026, 5:25 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Creation of a direct financial obligation · Financial statements and exhibits
8-KAug. 6, 2026, 4:32 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KAug. 3, 2026, 9 a.m. ETView on SEC.gov
Amendments to articles or bylaws; fiscal year change · Regulation FD disclosure · Financial statements and exhibits